Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant...
Solidion Technology develops a new high-capacity, low-cost anode
Recently discovered anode is composed of low-cost silicon particles protected by a flexible rubber to significantly extend the range of commercial drones DALLAS, Dec. 15, 2025 /PRNewswire/ -- Solidion Technology, Inc. (Nasdaq: STI), an advanced...
ReTo Eco-Solutions Subsidiary Showcases Equipment and Intelligent Solutions at Excon 2025 to Advance India Market Presence
BEIJING, Dec. 12, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company") today announced that its wholly owned subsidiary, Beijing REIT Equipment Technology Co., Ltd. ("REIT Equipment"), is participating in Excon...
Yum China Announces US$460 Million Share Repurchase Agreements for First Half of 2026 as Part of US$1.5 Billion Full-Year Capital Return Plan
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Yum China Holdings, Inc. (the "Company" or "Yum China") (NYSE: YUMC and HKEX: 9987) announced that it has entered into share repurchase agreements in the U.S. and Hong Kong for an aggregate repurchase amount...
Asia Pacific Enterprise Awards (APEA) 2025 Philippines Celebrates Visionaries Driving the Nation's Next Growth Era
MANILA, Philippines, Dec. 12, 2025 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) Philippines 2025 celebrated the nation's most forward-thinking business leaders and high-performing enterprises, recognizing their pivotal role in shaping...
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a...
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior...
Utility Global and Kyocera Join Forces to Scale H2Gen® Manufacturing Globally for Economic Industrial Decarbonization
Partners are investing in high-volume production of electrochemical cells to meet global demand from Steel, Refining, Petrochemical and Chemical sectors HOUSTON, Dec. 12, 2025 /PRNewswire/ -- Utility Global ("Utility"), a U.S.-based global economic...
MMTEC, Inc. Announces Receipt of Nasdaq Decision Regarding Minimum Bid Price Deficiency
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on December 9, 2025, the Company...
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody)...